Ronald B Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8151695/publications.pdf Version: 2024-02-01



RONALD R MOORE

#	Article	IF	CITATIONS
1	FGD5 regulates endothelial cell PI3 kinaseâ€Î² to promote neoâ€angiogenesis. FASEB Journal, 2022, 36, e22080.	0.5	0
2	Achieving the "trifecta―with open versus minimally invasive partial nephrectomy. World Journal of Urology, 2021, 39, 1569-1575.	2.2	4
3	The FABP12/PPARγ pathway promotes metastatic transformation by inducing epithelialâ€toâ€mesenchymal transition and lipidâ€derived energy production in prostate cancer cells. Molecular Oncology, 2020, 14, 3100-3120.	4.6	30
4	PEG-PLGA nanospheres loaded with nanoscintillators and photosensitizers for radiation-activated photodynamic therapy. Acta Biomaterialia, 2020, 117, 335-348.	8.3	24
5	Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth. Oncogene, 2020, 39, 6480-6492.	5.9	11
6	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database. Canadian Urological Association Journal, 2019, 14, 24-30.	0.6	2
7	Renal transplant anastomotic pseudoaneurysms: Case report of open repair and endovascular management. IJU Case Reports, 2019, 2, 86-89.	0.3	3
8	Does intraâ€operative verapamil administration in kidney transplantation improve graft function. Clinical Transplantation, 2019, 33, e13635.	1.6	4
9	Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). Journal of Cancer Education, 2019, 34, 14-18.	1.3	0
10	Investigating the role of endothelial cellâ€specific p110β isoform of PI3K as a potential target for antiâ€angiogenic therapy. FASEB Journal, 2019, 33, lb9.	0.5	0
11	Human Sertoli cells support high levels of Zika virus replication and persistence. Scientific Reports, 2018, 8, 5477.	3.3	75
12	A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma. Journal of Endourology, 2017, 31, 645-650.	2.1	12
13	Deletion of <i>F4L</i> (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes antiâ€ŧumor immunity with superior safety in bladder cancer models. EMBO Molecular Medicine, 2017, 9, 638-654.	6.9	36
14	Quiz. American Journal of Kidney Diseases, 2017, 70, A9-A11.	1.9	0
15	Post-transplant lymphoproliferative disorder and management of residual mass post chemotherapy: Case report. International Journal of Surgery Case Reports, 2017, 38, 115-118.	0.6	3
16	Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. CMAJ Open, 2017, 5, E834-E841.	2.4	1
17	Renal transplant complications: Moving toward comparison of relevant parameters and further improvement in outcomes. Canadian Urological Association Journal, 2017, 11, 394-5.	0.6	0
18	Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative. Canadian Urological Association Journal, 2017, 11, 182.	0.6	33

RONALD B MOORE

#	Article	IF	CITATIONS
19	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. Canadian Urological Association Journal, 2017, 11, 232-7.	0.6	8
20	Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e17-486.e23.	1.6	25
21	The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 486.e1-486.e7.	1.6	37
22	Primary Metastatic Squamous Cell Carcinoma of the Male Urethra Presenting with Scrotal Abscess and Subsequent Development of Fournier's Gangrene. Clinical Medicine Insights: Case Reports, 2016, 9, CCRep.S40420.	0.7	7
23	Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase. European Urology, 2016, 69, 734-744.	1.9	66
24	Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis. PLoS ONE, 2015, 10, e0135245.	2.5	38
25	Surgical Management of Stage T1 Renal Tumors in Canadian Academic Centers. Canadian Urological Association Journal, 2015, 9, 99.	0.6	8
26	Prostate Perfusion Mapped by Technetium-99m Macroaggregated Albumin after Selective Arterial Injection. Journal of Vascular and Interventional Radiology, 2015, 26, 418-425.	0.5	3
27	Monitoring photodynamic therapy with photoacoustic microscopy. Journal of Biomedical Optics, 2015, 20, 106012.	2.6	15
28	Canadian guidelines for the management of the small renal mass (SRM). Canadian Urological Association Journal, 2015, 9, 160.	0.6	45
29	Detecting functional changes with [18F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy. EJNMMI Research, 2014, 4, 27.	2.5	14
30	Multimodality photoacoustic and Raman imaging of magnetically trapped tumor cells. , 2014, , .		1
31	Layered gadolinium-based nanoparticle as a novel delivery platform for microRNA therapeutics. Nanotechnology, 2014, 25, 425102.	2.6	21
32	Detection of circulating tumor cells using targeted surface-enhanced Raman scattering nanoparticles and magnetic enrichment. Journal of Biomedical Optics, 2014, 19, 056014.	2.6	47
33	The Value of "Liver Windows―Settings in the Detection of Small Renal Cell Carcinomas on Unenhanced Computed Tomography. Canadian Association of Radiologists Journal, 2014, 65, 71-76.	2.0	21
34	A molecular complex of bovine milk protein and oleic acid selectively kills cancer cellsin vitroand inhibits tumour growth in an orthotopic rat bladder tumour model. BJU International, 2013, 112, E201-E210.	2.5	19
35	Using the Delphi Technique to Improve Clinical Outcomes Through the Development of Quality Indicators in Renal Cell Carcinoma. Journal of Oncology Practice, 2013, 9, e262-e267.	2.5	43
36	Protecting transplant recipients and live renal donors: Facing the challenges. Canadian Urological Association Journal, 2013, 7, 46.	0.6	0

RONALD B MOORE

#	Article	IF	CITATIONS
37	Oncolytic Viruses in the Treatment of Bladder Cancer. Advances in Urology, 2012, 2012, 1-11.	1.3	19
38	Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL. International Journal of Oncology, 2011, 39, 61-71.	3.3	6
39	Adverse Renal Outcomes in Subjects Undergoing Nephrectomy for Renal Tumors: A Population-Based Analysis. European Urology, 2011, 59, 333-339.	1.9	69
40	Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S7658.	1.3	14
41	The Prognostic Utility of Deceased Donor Implantation Biopsy in Determining Function and Graft Survival After Kidney Transplantation. Transplantation, 2010, 89, 559-566.	1.0	61
42	Bladder outlet obstruction: progression from inflammation to fibrosis. BJU International, 2010, 106, 1686-1694.	2.5	153
43	Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. Photodiagnosis and Photodynamic Therapy, 2010, 7, 106-114.	2.6	8
44	Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology, 2009, 20, 375101.	2.6	261
45	Response of Bladder Carcinoma Cells to TRAIL and Antisense Oligonucleotide, Bcl-2 or Clusterin Treatments. Journal of Urology, 2009, 181, 1361-1371.	0.4	8
46	Associations Between Comorbidity, and Overall Survival and Bladder Cancer Specific Survival After Radical Cystectomy: Results From the Alberta Urology Institute Radical Cystectomy Database. Journal of Urology, 2009, 182, 85-93.	0.4	53
47	The Transcriptome of the Implant Biopsy Identifies Donor Kidneys at Increased Risk of Delayed Graft Function. American Journal of Transplantation, 2008, 8, 78-85.	4.7	100
48	Photodynamic Therapy of the Canine Prostate: Intra-arterial Drug Delivery. CardioVascular and Interventional Radiology, 2008, 31, 164-176.	2.0	8
49	Associations Among Age, Comorbidity and Clinical Outcomes After Radical Cystectomy: Results From the Alberta Urology Institute Radical Cystectomy Database. Journal of Urology, 2008, 180, 128-134.	0.4	84
50	Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles. Clinical and Investigative Medicine, 2008, 31, 160.	0.6	138
51	Dosimetric considerations of interstitial photodynamic therapy of the canine prostate mediated by intra-arterially administered hypocrellin derivative. Proceedings of SPIE, 2008, , .	0.8	1
52	Fractionated versus Standard Continuous Light Delivery in Interstitial Photodynamic Therapy of Dunning Prostate Carcinomas. Clinical Cancer Research, 2007, 13, 7496-7505.	7.0	49
53	Interstitial Photodynamic Therapy of the Canine Prostate Using Intra-Arterial Administration of Photosensitizer and Computerized Pulsed Light Delivery. Journal of Urology, 2007, 178, 308-313.	0.4	7
54	A comparison of susceptibility to photodynamic treatment between endothelial and tumor cells in vitro and in vivo. Photodiagnosis and Photodynamic Therapy, 2007, 4, 160-169.	2.6	10

Ronald B Moore

#	Article	IF	CITATIONS
55	Using fluorescence to augment the efficacy of photodynamic therapy. , 2006, , .		2
56	A NOVEL INTRAVESICAL THERAPY FOR SUPERFICIAL BLADDER CANCER IN AN ORTHOTOPIC MODEL: ONCOLYTIC REOVIRUS THERAPY. Journal of Urology, 2004, 172, 2018-2022.	0.4	34
57	Light dosimetry for multiple cylindrical diffusing sources for use in photodynamic therapy. Physics in Medicine and Biology, 2004, 49, 3197-3208.	3.0	23
58	The effect of photodynamic therapy on rat urinary bladder with orthotopic urothelial carcinoma. BJU International, 2003, 92, 125-130.	2.5	12
59	Whole Bladder Photodynamic Therapy for Orthotopic Superficial Bladder Cancer in Rats: A Study of Intravenous and Intravesical Administration of Photosensitizers. Journal of Urology, 2003, 169, 352-356.	0.4	22
60	In vitro senescence occurring in normal human endothelial cells can be rescued by ectopic telomerase activity. Transplantation Proceedings, 2003, 35, 2483-2485.	0.6	18
61	Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Research, 2003, 93, 1-12.	2.2	40
62	Fractionated PDT light delivery system based on fiber optic switching technology. , 2003, , .		3
63	Leiomyosarcoma of the Bladder in a Retinoblastoma Patient. Urologia Internationalis, 2003, 71, 118-121.	1.3	18
64	Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers. Journal of Urology, 2003, 169, 352-6.	0.4	4
65	Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anti-Cancer Drugs, 2002, 13, 557-566.	1.4	39
66	<title>Predicting fluence measurements from a cylindrical diffusing tip using the P3-approximation</title> ., 2002,,.		0
67	Interstitial photodynamic therapy in subcutaneously implanted urologic tumors in rats after intravenous administration of 5-aminolevulinic acid. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 125-132.	1.6	21
68	<title>Using radiance predicted by the P3 approximation in a spherical geometry to predict tissue optical properties</title> ., 2001,,.		4
69	Light dosimetry using the P3 approximation. Physics in Medicine and Biology, 2001, 46, 2359-2370.	3.0	28
70	Using radiance predicted by the P3-approximation for treatment planning for PDT for prostatic carcinoma. , 2001, , .		0
71	Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon γ-1b for the treatment of metastatic renal cell carcinoma. BJU International, 2001, 86, 613-618.	2.5	48
72	Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. British Journal of Cancer, 1999, 81, 638-646.	6.4	97

RONALD B MOORE

#	Article	IF	CITATIONS
73	Biodistribution of Photofrin II® and 5-Aminolevulinic Acid-Induced Protoporphyrin IX in Normal Rat Bladder and Bladder Tumor Models: Implications for Photodynamic Therapy. Photochemistry and Photobiology, 1998, 67, 573-583.	2.5	20
74	Radiance modelling using the P3 approximation. Physics in Medicine and Biology, 1998, 43, 3559-3570.	3.0	21
75	Biodistribution of Photofrin II® and 5-Aminolevulinic Acid-Induced Protoporphyrin IX in Normal Rat Bladder and Bladder Tumor Models: Implications for Photodynamic Therapy. Photochemistry and Photobiology, 1998, 67, 573-583.	2.5	28
76	Monte Carlo modelling of angular radiance in tissue phantoms and human prostate: PDT light dosimetry. Physics in Medicine and Biology, 1997, 42, 1675-1687.	3.0	40
77	Preclinical Assessment of Hypocrellin B and Hypocrellin B Derivatives as Sensitizers for Photodynamic Therapy of Cancer: Progress Update. Photochemistry and Photobiology, 1997, 65, 714-722.	2.5	93
78	In vivo light transmission spectra in EMT6/Ed murine tumors and dunning R3327 rat prostate tumors during photodynamic therapy. , 1997, 21, 124-133.		8
79	Photosensitization by anticancer agents 21: New perylene- and aminonaphthoquinones. Free Radical Biology and Medicine, 1996, 20, 589-593.	2.9	31
80	Hypocrellins as photosensitizers for photodynamic therapy: a screening evaluation and pharmacokinetic study. Cancer Chemotherapy and Pharmacology, 1996, 37, 343-350.	2.3	60
81	Anisotropy of radiance in tissue phantoms and Dunning R3327 rat tumors: Radiance measurements with flat cleaved fiber probes. , 1996, 19, 471-479.		6
82	UPTAKE KINETICS AND INTRACELLULAR LOCALIZATION OF HYPOCRELLIN PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY: A CONFOCAL MICROSCOPY STUDY. Photochemistry and Photobiology, 1995, 61, 632-638.	2.5	51
83	Synthesis and biodistribution of 14C-radiolabelled hypocrellin B. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 815-823.	1.0	15
84	Non-invasive monitoring of photodynamic therapy with 99technetium HMPAO scintigraphy. British Journal of Cancer, 1992, 65, 491-497.	6.4	20